1. Home
  2. FSK vs CYTK Comparison

FSK vs CYTK Comparison

Compare FSK & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSK
  • CYTK
  • Stock Information
  • Founded
  • FSK 2007
  • CYTK 1997
  • Country
  • FSK United States
  • CYTK United States
  • Employees
  • FSK N/A
  • CYTK N/A
  • Industry
  • FSK Investment Managers
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSK Finance
  • CYTK Health Care
  • Exchange
  • FSK Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • FSK 5.4B
  • CYTK 4.4B
  • IPO Year
  • FSK N/A
  • CYTK 2004
  • Fundamental
  • Price
  • FSK $17.72
  • CYTK $38.05
  • Analyst Decision
  • FSK Hold
  • CYTK Buy
  • Analyst Count
  • FSK 7
  • CYTK 13
  • Target Price
  • FSK $19.57
  • CYTK $71.58
  • AVG Volume (30 Days)
  • FSK 2.6M
  • CYTK 1.5M
  • Earning Date
  • FSK 08-06-2025
  • CYTK 08-07-2025
  • Dividend Yield
  • FSK 15.80%
  • CYTK N/A
  • EPS Growth
  • FSK N/A
  • CYTK N/A
  • EPS
  • FSK 0.78
  • CYTK N/A
  • Revenue
  • FSK $1,646,000,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • FSK N/A
  • CYTK $27.08
  • Revenue Next Year
  • FSK N/A
  • CYTK $652.09
  • P/E Ratio
  • FSK $22.77
  • CYTK N/A
  • Revenue Growth
  • FSK N/A
  • CYTK 2635.74
  • 52 Week Low
  • FSK $17.35
  • CYTK $29.31
  • 52 Week High
  • FSK $24.10
  • CYTK $59.39
  • Technical
  • Relative Strength Index (RSI)
  • FSK 26.39
  • CYTK 56.78
  • Support Level
  • FSK $17.35
  • CYTK $32.89
  • Resistance Level
  • FSK $17.98
  • CYTK $39.45
  • Average True Range (ATR)
  • FSK 0.42
  • CYTK 1.65
  • MACD
  • FSK -0.11
  • CYTK 0.18
  • Stochastic Oscillator
  • FSK 11.79
  • CYTK 78.66

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: